Pantogam pills 250mg №50
All payments are encrypted via SSL
Full Refund if you haven't received your order
Pharmacotherapeutic group: nootropic agent.
The spectrum of action of Pantogam® is associated with the presence of gamma-aminobutyric acid in its structure. The mechanism of action is due to the direct influence of Pantogam® on the GABA receptor-channel complex. The drug has a nootropic and anticonvulsant action. Pantogam® increases brain resistance to hypoxia and the effects of toxic substances, stimulates anabolic processes in neurons, combines a moderate sedative effect with a mild stimulating effect, reduces motor excitability, and activates mental and physical performance. Improves GABA metabolism in chronic alcohol intoxication and after the abolition of ethanol. It is able to inhibit acetylation reactions involved in the inactivation mechanisms of procaine (novocaine) and sulfonamides, which results in a prolonged action of the latter. It causes inhibition of the pathologically increased gallbladder reflex and detrusor tone.
Pantogam® is rapidly absorbed from the gastrointestinal tract, penetrates the blood-brain barrier, the highest concentrations are created in the liver, kidneys, in the wall of the stomach and skin. The drug is not metabolized and is excreted unchanged within 48 hours: 67.5% of the dose taken - with urine, 28.5% - with feces.
Indications and usage
- cognitive impairment in organic brain lesions, including the effects of neuroinfections and craniocerebral injuries, and neurotic disorders;
- schizophrenia with cerebral organic deficiency;
- extrapyramidal disorders (myoclonus epilepsy, Huntington's chorea, hepatolenticular degeneration, Parkinson's disease, etc.), as well as for the treatment and prevention of extrapyramidal syndrome (hyperkinetic and akinetic) caused by the administration of neuroleptics;
- epilepsy with a slowdown of mental processes in complex therapy with anticonvulsants;
- psycho-emotional overload, reduced mental and physical performance, to improve concentration and memorization;
- neurogenic urination disorders (pollakiuria, urgency, imperative urinary incontinence, enuresis);
- children with developmental delay (mental, speech, motor, or a combination thereof), including against the background of perinatal encephalopathy and in children with various forms of cerebral palsy;
- children with hyperkinetic disorders (attention deficit hyperactivity syndrome);
- children with neurosis-like conditions (tikah; stuttering, mainly in the clonic form).
- acute severe kidney disease;
- breastfeeding period;
- children up to 3 years
In conditions of long-term treatment, simultaneous administration of the drug with other nootropic and stimulating agents is not recommended.
Pregnancy and Breastfeeding
The use of the drug during pregnancy and during breastfeeding is not recommended due to the lack of experience of clinical use in this category of patients.
Inside, in 15-30 minutes after eating. A single dose for adults is usually 0.25-1 g (1-4 tablets), for children - 0.25-0.5 g (1-2 tablets); daily intake for adults - 1.5-3 g (6-12 tablets), for children - 0.75-3 g (3-12 tablets). The course of treatment is from 1 to 4 months, in some cases up to 6 months. After 3-6 months, it is possible to repeat the course of treatment. For cognitive impairment with organic brain lesions, including the effects of neuroinfections and head injuries, and neurotic disorders: 0.25 g (1 tablet) 3-4 times a day. For extrapyramidal disorders (myoclonus epilepsy, Chorea cholera, hepatolenticular degeneration, Parkinson's disease, etc.): at a dose of 0.5 to 3 g (2-12 tablets) per day. The course of treatment is up to 4 months or more.
In the treatment and prevention of extrapyramidal syndrome (hyperkinetic and akinetic), caused by the administration of antipsychotics in schizophrenia with cerebral organic failure:
adults - at a dose of 0.5 to 1 g (2-4 tablets) 3 times a day; children - at a dose of 0.25 to 0.5 g (1-2 tablets) 3-4 times a day. The course of treatment is 1-3 months. In epilepsy with a slowdown of mental processes in complex therapy with anticonvulsant drugs: adults - at a dose of 0.5 to 1 g (2-4 tablets) 3 times a day; children - at a dose of 0.25 to 0.5 g (1-2 tablets) 3-4 times a day. The course of treatment is up to 6 months. When psychoemotional overload, reducing mental and physical performance, to improve concentration and memory: 0.25 g (1 tablet) 3 times a day. For neurogenic disorders of urination: for adults - at a dose of 0.5 to 1 g (2-4 tablets) 2-3 times a day; children - at a dose of 0.25 to 0.5 g (1-2 tablets) 3 times a day (daily dose is 25-50 mg / kg). The course of treatment is 1-3 months.
Children with various pathologies of the nervous system, depending on age, are advised to take up to 3 g per day (12 tablets). Tactics of administration of the drug: increasing the dose within 7-12 days, taking the maximum dose for 15-40 days and gradually reducing the dose until Pantogam® is canceled within 7-8 days. The interval between Pantogam® coursework, as for any other nootropic agent, is from 1 to 3 months. Children with developmental delay: 0.5 g (2 tablets) 3-4 times a day. The course of treatment is 2-3 months.For children with attention deficit hyperactivity syndrome: at a dose of 0.25 to 1 g (1-4 tablets) 1-2 times a day in the morning and afternoon with dose titration for the first 5-7 days (the average therapeutic dose is 30 mg / kg of body weight of the child per day). The course of treatment is 3-4 months. Children with neurosis-like conditions (ticks; stuttering, mainly in the clonic form): at a dose of 0.25 to 0.5 g (1-2 tablets) 3-6 times a day. The course of treatment is 1-4 months. Taking into account the nootropic action of the drug, its administration is carried out preferably in the morning and afternoon hours (up to 17 hours).
The drug is used in children older than 3 years. At an earlier age, it is recommended to take the drug in the form of a syrup.
At a temperature not higher than 25 ° С. Keep out of the reach of children.